Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management
J Jordan, AL Birkenfeld, O Melander, C Moro - Hypertension, 2018 - Am Heart Assoc
Jordan et al Natriuretic Peptides and Cardiometabolic Crosstalk 271 adjustment for
traditional risk factors. 8 The overall association was primarily explained by excess diabetes …
traditional risk factors. 8 The overall association was primarily explained by excess diabetes …
Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment
K Yamamoto, H Rakugi - Hypertension Research, 2021 - nature.com
Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents
characterized by their dual action on the major regulators of the cardiovascular system …
characterized by their dual action on the major regulators of the cardiovascular system …
Hydrogen bonds between valsartan and solvents (water and methanol): Evidences for solvation dynamics using local energy decomposition and abinitio molecular …
T Pooventhiran, R Thomas - Journal of Molecular Liquids, 2022 - Elsevier
The change in Gibbs energy when an ion or molecule moves from a vacuum to a solvent is
known as solvation energy and solvation is the process of attracting and associating …
known as solvation energy and solvation is the process of attracting and associating …
Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice
P Wang, R Guo, X Bai, W Cui, Y Zhang, H Li… - Frontiers in …, 2022 - frontiersin.org
Background Diabetic kidney disease (DKD), as a serious microvascular complication of
diabetes, has limted treatment options. It is reported that the Sacubitril/Valsartan (Sac/Val) …
diabetes, has limted treatment options. It is reported that the Sacubitril/Valsartan (Sac/Val) …
PDE9 inhibition activates PPARα to stimulate mitochondrial fat metabolism and reduce cardiometabolic syndrome
Central obesity with cardiometabolic syndrome (CMS) is a major global contributor to human
disease, and effective therapies are needed. Here, we show inhibiting cyclic-GMP selective …
disease, and effective therapies are needed. Here, we show inhibiting cyclic-GMP selective …
Potential uses of sacubitril/valsartan: need for data on efficacy and safety
F Huet, M Akodad, E Kalmanovitch, J Adda… - American Journal of …, 2019 - Springer
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the
cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades …
cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades …
cGMP manipulation in cardiometabolic disease: chances and challenges
Enhancing cGMP signaling through nonpharmacological or pharmacological means may
improve glucose metabolism in addition to affecting the cardiovascular system. However …
improve glucose metabolism in addition to affecting the cardiovascular system. However …
Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
M Nikolic, J Novakovic, G Ramenskaya… - Diabetology & Metabolic …, 2022 - Springer
Background It is a growing importance to induce a new treatment approach to encourage
weight loss but also to improve maintenance of lost weight. It has been shown that …
weight loss but also to improve maintenance of lost weight. It has been shown that …